Teysuno (gimeracil/oteracil/tegafur)

Preoperative DOS for gastric cancer with ELM yielded unprecedentedly favorable 3-year survival outcomes and was considered a provisional standard of care without a phase III trial within our JCOG community.

P2, N=92, Not yet recruiting, Cancer Institute and Hospital, Chinese Academy of Medical Sciences

As postoperative adjuvant therapy, she received four cycles of doxorubicin and cyclophosphamide during pregnancy, followed by four cycles of docetaxel after delivery, along with tamoxifen and tegafur-gimeracil-oteracil potassium. She underwent staged risk-reducing salpingo-oophorectomy and CRRM after surgery for left breast cancer. Even in pregnancy-associated breast cancer complicated by HBOC, management should be individualized with careful consideration of safety, and the timing of each intervention should be determined according to the specific clinical circumstances of each patient.

P2, N=32, Recruiting, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Trial completion date: Sep 2026 --> Sep 2028 | Trial primary completion date: Mar 2026 --> Mar 2028

To address the parallel needs for high QOL and disease control, we developed an alternative therapeutic approach termed"Coexistence Therapy for Cancer,"employing the combination of a carbohydrate-restricted ketogenic diet, metformin, vitamin-D, eicosapentaenoic acid (EPA) and additional complementary therapies, with S-1 (tegafur/gimeracil/oteracil potassium) at doses low enough to avoid side effects. These findings suggest that this therapeutic strategy may serve as a complementary treatment option for patients who are unable to tolerate standard chemotherapy. Further accumulation of clinical cases is required to validate the effectiveness of this approach.

P2, N=90, Recruiting, Innovent Biologics (Suzhou) Co. Ltd. | Not yet recruiting --> Recruiting

P2, N=48, Not yet recruiting, Shanghai Changzheng Hospital

Our weighted scoring system identifies high-risk patients who derive limited benefit from standard adjuvant S-1. Such individuals may be candidates for intensified postoperative strategies.

Neoadjuvant serplulimab plus SOX followed by adjuvant serplulimab significantly improved event-free survival and demonstrated a better safety profile compared with neoadjuvant and adjuvant SOX in PD-L1-positive, resectable gastric or gastro-oesophageal junction adenocarcinoma. Extended follow-up for the overall survival data is warranted to confirm a survival advantage of this perioperative strategy with a chemotherapy-sparing adjuvant component for this indication.

Tegafur/gimeracil/oteracil (S-1) was administered as adjuvant therapy, however, liver metastasis recurred 3 years after surgery. Modified FOLFIRINOX (FFX) was administered for 1 year, and the metastasis was limited to a solitary lesion on the surface of the liver...Olaparib maintenance therapy was selected for germline BRCA2 mutation positive. The liver metastases disappeared, and the therapeutic effect was maintained for one year without any noticeable adverse events. More than 9 years after the initial surgery, the patient is continuing treatment with good performance status.

After neoadjuvant chemotherapy (docetaxel +oxaliplatin + S-1: DOS), he underwent proximal gastrectomy, double tract reconstruction and para-aortic lymph node dissection...In November 2021, the patient presented with para-aortic lymph node recurrence and was treated with S-1 + oxaliplatin (SOX) + trastuzumab (Tmab) and paclitaxel + ramucirumab, but the lymph nodes were enlarged and trastuzumab deruxtecan (T-DXd) therapy was started...T-DXd was approved for the treatment of HER2-positive unresectable advanced or recurrent gastric cancer from the 6th edition of Gastric Cancer Treatment Guidelines. We report a case of long-term CR maintenance after T-DXd therapy for recurrent esophagogastric junction gastric cancer.

P1, N=70, Recruiting, Chang Gung Memorial Hospital | Trial completion date: Jul 2026 --> Dec 2028 | Trial primary completion date: Jul 2026 --> Dec 2027